Cholera Therapeutics Pipeline Review, H1 2015 offers “Cholera – Pipeline Review, H1 2015”global research report on its store.

This report provides comprehensive information on the therapeutic development for Cholera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available at .

Scope of The Report:

  • The report provides a snapshot of the global therapeutic landscape of Cholera
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cholera and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cholera pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy This Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cholera
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a copy of this report at .

Table of Content for “Cholera – Pipeline Review, H1 2015” research report includes:

Cholera Overview 6

Therapeutics Development 7

Pipeline Products for Cholera - Overview 7

Pipeline Products for Cholera - Comparative Analysis 8

Cholera - Therapeutics under Development by Companies 9

Cholera - Therapeutics under Investigation by Universities/Institutes 10

Cholera - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Cholera - Products under Development by Companies 14

Cholera - Products under Investigation by Universities/Institutes 15

Cholera - Companies Involved in Therapeutics Development 16

Beijing Minhai Biotechnology Co., Ltd 16

Napo Pharmaceuticals, Inc. 17

PaxVax 18

Cholera - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 23

Drug Profiles 25

AKT-10082 - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

cholera (trivalent) vaccine - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

crofelemer DR - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

PXVX-0200 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Cholera - Recent Pipeline Updates 31

Cholera - Dormant Projects 35

Cholera - Discontinued Products 36

Cholera - Product Development Milestones 37

Featured News & Press Releases 37

Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial 37

Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum 37

Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 38

May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 39

Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 39

Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 41

Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 42

Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccine 42

Priced at US $2000 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( ).